AZD-5423

AZD-5423
Identifiers
	IUPAC name 2,2,2-Trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide;
CAS Number	1034148-04-3 ;
PubChem CID	24825740;
ChemSpider	28536140;
UNII	641H0Q518W;
CompTox Dashboard (EPA)	DTXSID40145823 ;
ECHA InfoCard	100.205.965
Chemical and physical data
Formula	C25H21F4N3O3
Molar mass	487.455 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]([C@@H](c1cccc(c1)OC)Oc2ccc3c(c2)cnn3c4ccc(cc4)F)NC(=O)C(F)(F)F;
	InChI InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1; Key:FCNQMDSJHADDFT-WNSKOXEYSA-N;

AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca^[1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.^[2]^[3]^[4]^[5]^[6]

Quick facts Identifiers, CAS Number ...

Close

It has completed a phase II clinical trial.^[7]

See also

Identifiers

IUPAC name 2,2,2-Trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide
CAS Number	1034148-04-3^Y
PubChem CID	24825740
ChemSpider	28536140
UNII	641H0Q518W
CompTox Dashboard (EPA)	DTXSID40145823
ECHA InfoCard	100.205.965
Chemical and physical data
Formula	C₂₅H₂₁F₄N₃O₃
Molar mass	487.455 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H]([C@@H](c1cccc(c1)OC)Oc2ccc3c(c2)cnn3c4ccc(cc4)F)NC(=O)C(F)(F)F
InChI InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1 Key:FCNQMDSJHADDFT-WNSKOXEYSA-N